There are 2949 resources available
Welcome and Introduction
Presenter: James Larkin
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Clinical Lessons Learned From the Use of Dual I-O Therapy
Presenter: James Larkin
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Exploring Treatment Advancements in aRCC with CTLA-4 and PD-1 Inhibition
Presenter: Nizar Tannir
Session: Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC
Resources:
Webcast
Welcome and introduction
Presenter: Rosario Garcia Campelo
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
EGFR+ NSCLC: A personalised sequencing approach
Presenter: Jesus Corral Jaime
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
ALK+ and ROS1+ NSCLC: Optimising patient outcomes
Presenter: Todd Bauer
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
Live Q&A - 18 September 2020 - 15:30-16:00
Presenter: Pilar Garrido
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast
Welcome and Introduction: Evolution of patient care in HER2-positive eBC
Presenter: Eva Ciruelos
Session: F. Hoffmann-La Roche - Transforming patient care: Leveraging the latest clinical data in HER2-positive eBC
Resources:
Webcast
How to ensure optimal treatment for patients with residual disease
Presenter: Andrew Wardley
Session: F. Hoffmann-La Roche - Transforming patient care: Leveraging the latest clinical data in HER2-positive eBC
Resources:
Webcast
Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma
Presenter: Silvia Novello
Session: Boehringer Ingelheim - Focus on NSCLC treatment options
Resources:
Webcast